Anti-IL-5 Agents for the Treatment of Idiopathic Chronic Eosinophilic Pneumonia: A Case Series

References

• Suzuki Y, Suda T. Eosinophilic pneumonia: a review of the previous literature, causes, diagnosis, and management. Allergol Int. 2019;68(4):413–419. doi:10.1016/j.alit.2019.05.006
   PubMed Web of Science ®Google Scholar
• Naughton M, Fahy J, FitzGerald MX. Chronic eosinophilic pneumonia. A long-term follow-up of 12 patients. Chest. 1993;103(1):162–165. doi:10.1378/chest.103.1.162
   PubMed Web of Science ®Google Scholar
• Rosenberg CE, Khoury P. Approach to eosinophilia presenting with pulmonary symptoms. Chest. 2021;159(2):507–516. doi:10.1016/j.chest.2020.09.247
   PubMed Web of Science ®Google Scholar
• Barry J, Gadre A, Akuthota P. Hypersensitivity pneumonitis, allergic bronchopulmonary aspergillosis and other eosinophilic lung diseases. Curr Opin Immunol. 2020;66:129–135. doi:10.1016/j.coi.2020.10.005
   PubMed Web of Science ®Google Scholar
• Marchand E, Cordier JF. Idiopathic chronic eosinophilic pneumonia. Orphanet J Rare Dis. 2006;1:11. doi:10.1186/1750-1172-1-11
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Suda T. Long-term management and persistent impairment of pulmonary function in chronic eosinophilic pneumonia: a review of the previous literature. Allergol Int. 2018;67(3):334–340. doi:10.1016/j.alit.2017.12.004
   PubMed Web of Science ®Google Scholar
• Marchand E, Reynaud-Gaubert M, Lauque D, Durieu J, Tonnel AB, Cordier JF. Idiopathic chronic eosinophilic pneumonia. A clinical and follow-up study of 62 cases. The Groupe d’Etudes et de Recherche sur les Maladies “Orphelines” Pulmonaires (GERM”O”P). Medicine. 1998;77(5):299–312. doi:10.1097/00005792-199809000-00001
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Oyama Y, Hozumi H, et al. Persistent impairment on spirometry in chronic eosinophilic pneumonia: a longitudinal observation study (Shizuoka-CEP study). Ann Allergy Asthma Immunol. 2017;119(5):422–428 e2.
   PubMed Web of Science ®Google Scholar
• Ishiguro T, Takayanagi N, Uozumi R, et al. The long-term clinical course of chronic eosinophilic pneumonia. Intern Med. 2016;55(17):2373–2377. doi:10.2169/internalmedicine.55.6765
   PubMed Web of Science ®Google Scholar
• Oyama Y, Fujisawa T, Hashimoto D, et al. Efficacy of short-term prednisolone treatment in patients with chronic eosinophilic pneumonia. Eur Respir J. 2015;45(6):1624–1631. doi:10.1183/09031936.00199614
   PubMed Web of Science ®Google Scholar
• Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703. doi:10.1183/13993003.00703-2018
   PubMed Web of Science ®Google Scholar
• Ortega HG, Liu MC, Pavord ID, et al. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med. 2014;371(13):1198–1207. doi:10.1056/NEJMoa1403290
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled Phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol. 2015;16(1):45–56.
   PubMed Web of Science ®Google Scholar
• Vantaggiato L, Perruzza M, Refini RM, et al. Mepolizumab and benralizumab in severe eosinophilic asthma: preliminary results of a proteomic study. Lung. 2020;198(5):761–765. doi:10.1007/s00408-020-00379-6
   PubMed Web of Science ®Google Scholar
• Laviolette M, Gossage DL, Gauvreau G, et al. Effects of benralizumab on airway eosinophils in asthmatic patients with sputum eosinophilia. J Allergy Clin Immunol. 2013;132(5):1086–1096 e5. doi:10.1016/j.jaci.2013.05.020
   PubMed Web of Science ®Google Scholar
• Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344–1353 e2. doi:10.1016/j.jaci.2010.04.004
   PubMed Web of Science ®Google Scholar
• Menzies-Gow A, Flood-Page P, Sehmi R, et al. Anti-IL-5 (mepolizumab) therapy induces bone marrow eosinophil maturational arrest and decreases eosinophil progenitors in the bronchial mucosa of atopic asthmatics. J Allergy Clin Immunol. 2003;111(4):714–719. doi:10.1067/mai.2003.1382
   PubMed Web of Science ®Google Scholar
• Marchand E, Etienne-Mastroianni B, Chanez P, et al. Idiopathic chronic eosinophilic pneumonia and asthma: how do they influence each other? Eur Respir J. 2003;22(1):8–13.
   PubMed Web of Science ®Google Scholar
• Durieu J, Wallaert B, Tonnel AB. Long-term follow-up of pulmonary function in chronic eosinophilic pneumonia. Groupe d’Etude en Pathologie Interstitielle de la Societe de Pathologie Thoracique du Nord. Eur Respir J. 1997;10(2):286–291.
   PubMed Web of Science ®Google Scholar
• Matsuse H, Shimoda T, Fukushima C, et al. Diagnostic problems in chronic eosinophilic pneumonia. J Int Med Res. 1997;25(4):196–201. doi:10.1177/030006059702500404
   PubMed Web of Science ®Google Scholar
• Kubo H, Loegering DA, Adolphson CR, Gleich GJ. Cytotoxic properties of eosinophil granule major basic protein for tumor cells. Int Arch Allergy Immunol. 1999;118(2–4):426–428. doi:10.1159/000024154
   PubMed Web of Science ®Google Scholar
• McBrien CN, Menzies-Gow A. The biology of eosinophils and their role in asthma. Front Med. 2017;4:93.
   PubMed Web of Science ®Google Scholar
• Fukuchi M, Miyabe Y, Furutani C, et al. How to detect eosinophil ETosis (EETosis) and extracellular traps. Allergol Int. 2021;70(1):19–29. doi:10.1016/j.alit.2020.10.002
   PubMed Web of Science ®Google Scholar
• Adachi T, Alam R. The mechanism of IL-5 signal transduction. Am J Physiol. 1998;275(3):C623–C633.
   PubMed Web of Science ®Google Scholar
• Larose MC, Turcotte C, Chouinard F, et al. Mechanisms of human eosinophil migration induced by the combination of IL-5 and the endocannabinoid 2-arachidonoyl-glycerol. J Allergy Clin Immunol. 2014;133(5):1480–1482, 2 e1–3. doi:10.1016/j.jaci.2013.12.1081
   PubMed Web of Science ®Google Scholar
• Mould AW, Ramsay AJ, Matthaei KI, Young IG, Rothenberg ME, Foster PS. The effect of IL-5 and eotaxin expression in the lung on eosinophil trafficking and degranulation and the induction of bronchial hyperreactivity. J Immunol. 2000;164(4):2142–2150. doi:10.4049/jimmunol.164.4.2142
   PubMed Web of Science ®Google Scholar
• Katoh S, Matsumoto N, Matsumoto K, Fukushima K, Matsukura S. Elevated interleukin-18 levels in bronchoalveolar lavage fluid of patients with eosinophilic pneumonia. Allergy. 2004;59(8):850–856. doi:10.1111/j.1398-9995.2004.00492.x
   PubMed Web of Science ®Google Scholar
• Miyazaki E, Nureki S, Fukami T, et al. Elevated levels of thymus- and activation-regulated chemokine in bronchoalveolar lavage fluid from patients with eosinophilic pneumonia. Am J Respir Crit Care Med. 2002;165(8):1125–1131. doi:10.1164/ajrccm.165.8.2106110
   PubMed Web of Science ®Google Scholar
• Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi:10.1016/S2213-2600(15)00042-9
   PubMed Web of Science ®Google Scholar
• Kelly EA, Esnault S, Liu LY, et al. Mepolizumab attenuates airway eosinophil numbers, but not their functional phenotype, in asthma. Am J Respir Crit Care Med. 2017;196(11):1385–1395. doi:10.1164/rccm.201611-2234OC
   PubMed Web of Science ®Google Scholar
• Takano T, Inutsuka Y, Nakamura S, Ando N, Komori M. Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection. Respirol Case Rep. 2021;9(8):e00810. doi:10.1002/rcr2.810
   PubMed Web of Science ®Google Scholar
• Kisling A, Jones J, Hixson C, Hostler D, Hostler J. Mepolizumab: an alternative therapy for idiopathic chronic eosinophilic pneumonia with glucocorticoid intolerance. Drugs Context. 2020;9:1–7. doi:10.7573/dic.2020-5-3
   Google Scholar
• Izumo T, Kuse N, Awano N, et al. Rapid and sustained effects of a single dose of benralizumab on chronic eosinophilic pneumonia. Respir Med Case Rep. 2020;30:101062.
   PubMed Web of Science ®Google Scholar
• Shimizu Y, Kurosawa M, Sutoh Y, Sutoh E. Long-term treatment with anti-interleukin 5 antibodies in a patient with chronic eosinophilic pneumonia. J Investig Allergol Clin Immunol. 2020;30(2):154–155. doi:10.18176/jiaci.0468
   PubMed Web of Science ®Google Scholar
• To M, Kono Y, Yamawaki S, et al. A case of chronic eosinophilic pneumonia successfully treated with mepolizumab. J Allergy Clin Immunol Pract. 2018;6(5):1746–1748 e1. doi:10.1016/j.jaip.2018.06.017
   PubMed Web of Science ®Google Scholar
• Ricketti PA, Ricketti AJ. Relapsing chronic eosinophilic pneumonia treated successfully with benralizumab. Ann Allergy Asthma Immunol. 2021;126(6):726–727. doi:10.1016/j.anai.2021.02.016
   PubMed Web of Science ®Google Scholar
• Moran AM, Ramakrishnan S, Borg CA, et al. Blood eosinophil depletion with mepolizumab, benralizumab, and prednisolone in eosinophilic asthma. Am J Respir Crit Care Med. 2020;202(9):1314–1316. doi:10.1164/rccm.202003-0729LE
   PubMed Web of Science ®Google Scholar